When do you consider the addition of concurrent pembrolizumab to breast irradiation?
Would you consider administering Keytruda (pembrolizumab) concurrently with radiation therapy for the treatment of a patient with an ER-negative, PR-negative, HER2-negative pT2N1 breast cancer affecting the right chest wall and regional lymph nodes?
Answer from: Radiation Oncologist at Academic Institution
Based on the results of the KEYNOTE-522 study, in which during the adjuvant phase of the trial, any indicated RT was delivered concurrently with the adjuvant pembrolizumab cycles, I would consider the addition of pembrolizumab in this case, especially if the patient received neoadjuvant systemic che...
Answer from: Radiation Oncologist at Academic Institution
There are very few data yet on how best to combine immunotherapy and RT for patients with breast cancer, and even less for patients treated for local-regional disease. Verma and colleagues have just published a comprehensive review of this topic (Verma et al., PMID 38195030). The Institut Curie grou...
Answer from: Radiation Oncologist at Community Practice
Based on KEYNOTE data, we do this concurrently routinely. Also, this is a review and recommendation from the ESTRO group Meattini et al., PMID 38301705
Thank you